Total Voting Rights (1237C)
March 02 2011 - 2:00AM
UK Regulatory
TIDMMDST
RNS Number : 1237C
Medicsight Plc
02 March 2011
Press Release 02 March 2011
Medicsight PLC
("Medicsight" or "the Company")
Total Voting Rights
For the purposes of the Financial Services Authority's
Disclosure and Transparency Rules, the Company announces that as at
28 February 2011 the total number of ordinary shares of 5p in issue
is 155,524,904, with each share carrying the right to one vote.
The Company has no ordinary shares held in treasury. The total
number of voting rights in the Company is therefore 155,524,904.
This figure of 155,524,904 ordinary shares may therefore be used by
shareholders in the Company as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change in their interest in, the share capital of
the Company under the FSA's Disclosure and Transparency Rules.
-ENDS-
For further information:
Medicsight plc
Allan Rowley, CEO Tel: +44 (0)207 605 7950
www.medicsight.com
Daniel Stewart & Co
Noelle Greenaway / Oliver Rigby Tel: +44 (0) 207 776
6550
www.danielstewart.co.uk
Media enquiries:
Abchurch Communications
www.abchurch-group.com
Julian Bosdet Tel: +44 (0) 207 398
7700
julian.bosdet@abchurch-group.com
Simone Elviss Tel: +44 (0) 207 398
7728
simone.elviss@abchurch-group.com
Quincy Allan Tel: +44 (0) 207 398
7710
quincy.allan@abchurch-group.com
Notes to editors
Medicsight plc is a UK-headquartered, research driven, leading
developer of computer-aided detection (CAD) and image analysis
software for the medical imaging market. The CAD software
automatically highlights suspicious areas on computerised
tomography (CT) scans of the colon and lung, helping radiologists
to identify, measure and analyse potential disease and early
indicators of disease. Medicsight's CAD software has been developed
using a large and population diverse database of verified patient
CT scan data. Medicsight's ColonCAD(TM) and LungCAD(TM) software
products are seamlessly integrated with the advanced 3D
visualisation workstations of several industry-leading imaging
equipment partners.
About Computer-Aided Detection
With increasingly sophisticated radiological imaging hardware
such as Multi-Detector CT scanners, radiologists are facing a
growing challenge in the amount of detailed patient image data that
they must review for each patient examination. Some CT scan
examinations generate as many as 2000 images per patient. Review of
this data by the radiologist is not only time-consuming but also
prone to error due to reader fatigue. CAD software can help the
reviewing radiologist by analysing the image data and automatically
highlighting suspicious regions of interest for closer inspection.
Without CAD software some potential abnormalities or areas of
disease may be overlooked. This can be critical for diagnosis and
the management of patient outcomes as early detection of disease
greatly increases the probability of successful treatment and a
positive therapeutic outcome. In addition to supporting individual
radiologists CAD also has the potential to help standardise CT
interpretation across both individuals and institutions thereby
supporting population based screening programmes.
About Medicsight's CAD software
Medicsight's ColonCAD(TM) and LungCAD(TM) software use an
advanced CAD algorithm to analyse CT scans of the colon and lung
and automatically highlight suspicious areas that may be indicators
of disease. CAD may highlight areas easily overlooked by the
reviewing radiologist, such as small lesions or regions that are
hidden from view behind folds in the colon or normal structures and
surrounding tissue in the lung.
Both CAD products seamlessly integrate with the advanced 3D
visualisation platforms of industry-leading imaging equipment
partners. The integrated systems provide sophisticated image
viewing capabilities, including 3D reconstructed image data, with
the added advantage of demonstrating automatic CAD findings to
assist clinical end users in the detection and analysis of disease.
This allows clinical end users to perform either a 'second read',
where CAD findings are displayed to the user after completion of an
initial review of the CT scan data, or a 'concurrent read' where
CAD findings are displayed during the user's initial review of the
original CT scan images.
Since inception, Medicsight has developed close and lasting
relationships with some of the world's foremost clinicians in
product related areas. This provides the Company with a wealth of
clinical expertise and dedicated clinical research to support
ongoing product development. Medicsight also collaborates with a
number of leading academic institutions and clinical research
programmes worldwide to develop the Company's comprehensive
database of population diverse verified patient CT scan data, thus
allowing Medicsight's products to be validated to the highest
possible standards.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRSSDFMFFFSESD
Medicsight (LSE:MDST)
Historical Stock Chart
From Apr 2024 to May 2024
Medicsight (LSE:MDST)
Historical Stock Chart
From May 2023 to May 2024
